首页> 外文期刊>Acta Oto-Laryngologica >Preliminary study of proteomic shift from normal to premalignant laryngeal lesions and to laryngeal squamous cell carcinoma.
【24h】

Preliminary study of proteomic shift from normal to premalignant laryngeal lesions and to laryngeal squamous cell carcinoma.

机译:蛋白质组学从正常状态转变为恶变前的喉部病变,再到喉鳞状细胞癌的初步研究。

获取原文
获取原文并翻译 | 示例
       

摘要

CONCLUSIONS: The malignant shift was discovered to begin even in the premalignant stage in the comparison of premalignant laryngeal lesions (PMLLs) with laryngeal squamous cell carcinoma (LSCC) and healthy controls. The differential expression of proteins among normal, PMLL, and cancer cells might provide the prediction for the changes from normal to PMLL and to malignant disease. OBJECTIVES: To study the serum proteomic shift from normal control to PMLL and progression to LSCC. MATERIALS AND METHODS: A total of 211 serum samples from patients with LSCC (n = 89 at stage I-II) or PMLL (n = 57), or normal controls (n = 65) were obtained with informed consent. Serum protein profiles on weak cationic exchange (WCX2) were performed by surface-enhanced laser desorption/ionization mass spectrometry (SELDI-TOF MS) and then analyzed by Biomarker Wizard software. RESULTS: Peak intensities of serum from PMLLs were compared to normal controls and serum from patients with LSCC. Mean intensity differed significantly only for one peak (4532 Da, p = 0.032) between LSCC and precancerous diseases, while 13 peaks differed significantly between precancerous diseases and normal controls. Eighteen biomarkers were selected to separate stage I- II LSCC patients and healthy controls.
机译:结论:在比较恶性喉前病变(PMLLs)与喉鳞状细胞癌(LSCC)和健康对照者之间,发现恶性转移甚至开始于恶性前期。正常,PMLL和癌细胞之间蛋白质的差异表达可能为从正常到PMLL以及恶性疾病的变化提供预测。目的:研究血清蛋白质组学从正常对照向PMLL转变并发展为LSCC。材料与方法:在知情同意下,从211例LSCC(I-II期为89例)或PMLL(n = 57)或正常对照(n = 65)患者中获得了211份血清样品。通过表面增强激光解吸/电离质谱(SELDI-TOF MS)进行弱阳离子交换(WCX2)上的血清蛋白谱分析,然后通过Biomarker Wizard软件进行分析。结果:将PMLLs的血清峰值强度与正常对照和LSCC患者的血清峰值强度进行了比较。 LSCC和癌前疾病之间的平均强度仅在一个峰(4532 Da,p = 0.032)上有显着差异,而癌前疾病和正常对照组之间的13个峰之间存在显着差异。选择了18种生物标记物以分离I-II期LSCC患者和健康对照。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号